EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery

Artem S Grevtsev iD, Alexandra D Azarian, Alexey K Misorin iD, Daria O Chernyshova, Pavel A Iakovlev, Mikhail S Karbyshev

Biosensors · 2023

DOI: 10.3390/bios13121022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biosensors, 2023. Verfasst von Artem S Grevtsev und 5 weiteren Autor:innen. Beteiligte Einrichtung: JSC "BIOCAD", 198515 St. Peterburg, Russia. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The engineering of bispecific antibodies that exhibit optimal affinity and functional activity presents a significant scientific challenge. To tackle this, investigators employ an assortment of protein assay techniques, such as label-free interaction methodologies, which offer rapidity and convenience for the evaluation of extensive sample sets. These assays yield intricate data pertaining to the affinity towards target antigens and Fc-receptors, instrumental in predicting cellular test outcomes. Nevertheless, the fine-tuning of affinity is of paramount importance to mitigate potential adverse effects while maintaining efficient obstruction of ligand–receptor interactions. In this research, biolayer interferometry (BLI) was utilized to probe the functional characteristics of bispecific antibodies targeting cluster of differentiation 47 (CD47) and programmed death-ligand 1 (PD-L1) antigens, encompassing affinity, concurrent binding to two disparate antigens, and the inhibition of ligand–receptor interactions. The findings derived from BLI were juxtaposed with data from in vitro signal regulatory protein-α (SIRP-α)/CD47 blockade reporter bioassays for two leading bispecific antibody candidates, each demonstrating distinct affinity to CD47.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificNeoplasmsHumansCD47 AntigenB7-H1 AntigenLigandsProteins

Stichwörter der Autor:innen

BLICD47PD-L1affinityantibodiesbispecific antibodiescell-testskineticlabel-freereporter

Substanzen

Antibodies, BispecificCD47 AntigenB7-H1 AntigenLigandsProteinsCD47 protein, human

Autor:innen und Institutionen

  • JSC "BIOCAD", 198515 St. Peterburg, Russia.

ORCID-Profile: Artem S Grevtsev, Alexey K Misorin

Zitieren

APA

Grevtsev, A. S., Azarian, A. D., Misorin, A. K., Chernyshova, D. O., Iakovlev, P. A., & Karbyshev, M. S. (2023). Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery. Biosensors. https://doi.org/10.3390/bios13121022

Vancouver

Grevtsev AS, Azarian AD, Misorin AK, Chernyshova DO, Iakovlev PA, Karbyshev MS. Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery. Biosensors. 2023. doi:10.3390/bios13121022

BibTeX
@article{Grevtsev2023,
  author = {Grevtsev, Artem S and Azarian, Alexandra D and Misorin, Alexey K and Chernyshova, Daria O and Iakovlev, Pavel A and Karbyshev, Mikhail S},
  title = {Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery},
  journal = {Biosensors},
  year = {2023},
  doi = {10.3390/bios13121022}
}
Kostenlos starten →